Extended Data Fig. 9: Myopathic diseases are associated with decreased expression of GLUT4 and its trafficking machinery.
From: UBXN9 governs GLUT4-mediated spatial confinement of RIG-I-like receptors and signaling
a, Schematic of critical illness myopathy (CIM) and dermatomyositis (DM) studies. N = 7 CIM and 6 healthy controls; N = 39 DM and 20 healthy controls. b, Ingenuity Pathway Analysis (IPA) of the 6,257 differentially expressed genes (DEGs) (p < 0.05, fold change ≥ 1.5) in the CIM patients compared to healthy controls. Red circles highlight innate immune pathways activated in CIM patients compared to controls. c, Select DEGs in the canonical interferon pathways and SLC2A4 (GLUT4, red box) from (b). d, Expression of GLUT4 trafficking-related genes (FPKM) in dermatomyositis (DM) patients and healthy controls. e, Simple linear regression analysis of SLC2A4 or SLC2A1 expression with DDX58 and OAS1A in DM patients and healthy controls (IFITM1, IFIH1). For e, regression line + 95% confidence intervals (CI). Bar: mean ± SEM. P values determined by two-tailed Mann-Whitney test (d) or linear regression analysis (e).
